FDA expands approval of Imfinzi to reduce the risk of non-small cell lung cancer progressing

SILVER SPRING, Md., Feb. 16, 2018 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Imfinzi (durvalumab) for the treatment of patients with stage III non-small cell lung cancer (NSCLC) whose tumors are not able to be surgically removed (unresectable) and...